

Novel use of lycopene

- The present invention relates to a novel use of lycopene. More particularly, the invention relates to the use of lycopene for prevention, incidence risk reduction, coadjuvant treatment or treatment of non-cancerous symptoms and/or pathologies, which are
- 5 associated with, favored by or caused by androgen signalling, or which are sensitive to a reduction of androgen signalling. More specifically, the present invention relates to the use of lycopene in the primary prevention and incidence risk reduction of non-cancerous symptoms and/or pathologies (i.e., the prophylactic supplementation of healthy subjects), in the treatment or the coadjuvant treatment of non-cancerous symptoms and/or
- 10 pathologies (i.e. the supplementation as therapy or accompanying a running therapy) and in the secondary prevention of non-cancerous symptoms and/or pathologies (i.e., the supplementation after a successful therapy for the prevention of relapse), which are associated with, favored by or caused by androgen signalling or which are sensitive to a reduction of androgen signalling.
- 15 Androgen signalling is elementary for the development and maintenance of a variety of physiological functions. In males as well as in females, androgen signalling within physiological windows is necessary, and signalling intensities outside physiological ranges lead to symptoms or pathologies, whose shape or intensity alter according to androgen signalling level.
- 20 In the prostate (within benign prostate tissue), androgen signalling is necessary for the development and maintenance of prostate tissue architecture (Janulis L. et al., Prostate (2000) 43: 195-204, Huynh H. et al., J Endocrinol (2001) 171: 109-18, Kucway R. et al J Urol (2002) 167: 2443-7). In humans, the skin is a target of androgen signalling, where hair growth and sebum secretion are under androgen control. Especially female physiology
- 25 seems to be even more sensitive to altered androgen levels. An increased synthesis of androgen in the ovaries (Stein-Leventhal syndrome associated with polycystic ovary syndrome or amenorrhea) or in adrenals (due to carcinogenesis or hyperplasia), or a sensitization due to increased local metabolism within the skin, shows up clinically in dermatological symptoms like male-like hair growth (hirsutism) (Kelestimur F., J Pediatr

Endocrinol Metab (2001) 14 Suppl 5:1309-15; discussion 1317), alopecia (Mulinari-Brenner F & Bergfeld WF, Dermatol Nurs (2001) 13: 269-72, 277-8) and feminine acne (Vexiau P. et al., Ann Dermatol Venereol (2002) 129: 174-8, and Gynecol Obstet Fertil (2002) 30: 11-21). Polycystic ovary syndrome (PCOS) is the most frequent androgen
5 disorder of ovarian function. PCOS women are predisposed to infertility due to the chronic anovulation. At the same time they have been found to be profoundly insulin resistant. This baseline insulin resistance combined with the worsening effect of obesity (which may affect up to 75% of the US PCOS population), places these women at increased risk for impaired glucose tolerance and most likely diabetes. Women with PCOS
10 tend to have elevated triglycerides (perhaps the best lipid marker of insulin resistance), and an unfavorably elevated LDL (low density lipoproteins)/HDL (high density lipoproteins) ratio. A lowered HDL-C levels appear to be the strongest lipid predictor of cardiovascular mortality in women (Legro RS, Mol Cell Endocrinol (2002) 186: 219-25, Pugeat M. et al., Horm Res (2000) 54: 322-6, Jacobs DR Jr. et al, Am J Epidemiol (1990) 131: 32-47 and
15 Wilson PW. et al., Arteriosclerosis (1988) 8: 737-41) indicating an increased risk for cardiovascular diseases in PCOS patients.

According to the present invention, it has been found that androgen target gene expression in androgen sensitive target organ tissue, as the endpoint and result of androgen signalling, can be significantly reduced by the administration of lycopene or a combination of
20 lycopene and vitamin E.

The present invention, therefore, in one aspect is concerned with the use of lycopene in the manufacture of a composition for the primary and secondary prevention, incidence risk reduction, coadjuvant treatment or treatment of non-cancerous symptoms and/or pathologies, which are associated with, favored by or caused by androgen signalling, or
25 which are sensitive to a reduction of androgen signalling.

In another aspect, the present invention is concerned with a method of prevention or treatment of symptoms or pathologies associated with androgen signalling, which comprises administering to a subject (mammal or non-mammal, human or pet including birds and fish, or mammal or non-mammal farm animal) in need of such treatment for
30 therapy or prophylaxis an effective amount of lycopene.

In still another aspect, the invention is concerned with a method of treating non-cancerous symptoms and/or pathologies sensitive to lycopene comprising administering to a mammal, mammal or non-mammal pets including birds and fish, or mammal or non-

mammal farm animal in need of such treatment an amount of lycopene, wherein said amount leads to a reduction of androgen signalling.

In a preferred embodiment of the invention, lycopene is used together with vitamin E and/or vitamin C. Most preferred is a combination of lycopene, vitamin E and vitamin C.

- 5 The term vitamin E as used herein includes racemic vitamin E (D,L- α -tocopherol) or natural vitamin E, as well as derivatives thereof which have biological vitamin E activity, e.g. carboxylic acid esters, such as vitamin E acetate, propionate, butyrate or succinate; and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (also called Trolox[®]) and Trolox[®]-lipoate. The term vitamin C as used herein includes derivatives thereof, which
- 10 have biological vitamin C activity, e.g. esters and salts, such as sodium ascorbate, sodium ascorbyl phosphate, sodium ascorbyl polyphosphates and ascorbyl palmitate.

In a further embodiment of the invention, lycopene or lycopene in combination with vitamin E and/or vitamin C is used together with one or more of the following compounds:

- 15 (a) Silymarin (extract from *Silybum marianum*) and/or one or more derivatives thereof (silymarin dihemisuccinate sodium salt) and/or one or more of its four main components (silybin [synonymous with silibinin, and sometimes incorrectly called silybinin] and/or isosilybin and/or silydianin and/or silychristin) and/or one or more derivatives thereof (silybin-dihemisuccinate, disilybin, silybin-phosphatidylcholine complex, silybin-phosphate);
- 20 (b) Extract of Saw Palmetto (*Sabal serrulata*, syn. *Serenoa repens*) and/or one or more derivatives thereof and/or one or more of its main components being free fatty acids (lauric acid, oleic acid, myristic acid, palmitic acid and/or one or more derivatives thereof) and/or phytosterols (sitosterol, campesterol, stigmasterol, cycloartenol, sitostanol, campestanol and/or derivatives thereof (long-chain fatty acyl ester, ferrulate ester, glycosides));
- 25 (c) Genistein aglycone (4', 5, 7-trihydroxyisoflavone) and/or one or more derivatives thereof (genistein glucosides, genistein sulfates, genistein glucuronides);
- (d) Apigenin and/or one or more derivatives thereof;
- 30 (e) Quercetin (2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyrano-4-one) and/or dihydroquercetin and/or one or more derivatives thereof (quercetine

glucosides, quercetin glucuronides, quercetine sulphates, methylquercetin (isohamnetin (3'-O-methylquercetin), tamarixetin(4'-O-methylquercetin));

- (f) Myricetin and/or one or more derivatives thereof;
- (g) Kampferol and/or one or more derivatives thereof;
- 5 (h) Resveratrol (*cis*-3, 4', 5-trihydroxystilbene and/or *trans*-3, 4', 5-trihydroxystilbene) and/or one or more derivatives thereof (resveratrol glucosides, resveratrol sulfates, resveratrol glucuronides);
- (i) Curcumin (effects of *Curcuma Longa*) and/or one or more derivatives (demethoxycurcumin, bis-demethoxycurcumin, sodium curcumionate, bis-
10 demethylcurcumin, tetrahydrocurcumin, hexahydrocurcumin, diacetylcurcumin, triethylcurcumin) thereof and/or one or more of its main components (curcumin (diferuloylmethane), demethoxycurcumin, bisdemethoxycurcumin) and/or derivatives thereof (glucuronides, sulfates),
- (j) flufenamic acid and/or one or more derivatives (esters) thereof;
- 15 (k) geldanamycin
- (l) Extract of *Stephania hernandifolia* and/or one or more derivatives thereof and/or one or more of its components (e.g. 4-demethylhasubanonine, epistephanine) and/or derivatives thereof;
- (m) Extract of *Myrica rubra* and/or one or more derivatives thereof and/or one or more
20 of its components being diarylheptanoids (Quercetin, myricanone, myricanol, and myricetin) named acerogenin and their glycosides named aceroside and/or derivatives thereof;
- (n) Astaxanthin ((3S, 3'S)-3, 3'-dihydroxy- β , β -carotene-4, 4'-dione) and/or one or more isomers and/or monoesters and/or diesters, preferably esters of saturated
25 alcanoic acids, such as acetic, propionic, palmitic, stearic, and succinic acid, mono-unsaturated fatty acids, such as oleic acid, and poly-unsaturated fatty acids, such as linolic, linoleic, docosahexaenoic, and arachidonic acid;
- (o) β -Carotene and/or one or more isomers thereof;

- (p) β -Cryptoxanthin ((3R)- β , β -carotene-3-ol) and/or one or more isomers or esters thereof, preferably esters of saturated alkanoic acids, such as acetic, propionic, palmitic, stearic, and succinic acid, mono-unsaturated fatty acids, such as oleic acid, and poly-unsaturated fatty acids, such as linolic, linoleic, docosahexaenoic, and arachidonic acid;
- (q) (-)-Epigallocatechin gallate (EGCG) and/or (-)-epicatechin gallate (ECG) and/or one or more derivatives thereof;
- (r) Lutein ((3R, 3'R, 6'R)- β , ϵ , carotene-3, 3'-diol) and/or one or more isomers and/or monoesters and/or diesters, preferably esters of saturated alkanoic acids, such as acetic, propionic, palmitic, stearic, and succinic acid, mono-unsaturated fatty acids, such as oleic acid, and poly-unsaturated fatty acids, such as linolic, linoleic, docosahexaenoic, and arachidonic acid, thereof;
- (s) Rhizoxin and/or one or more derivatives thereof (palmitoyl rhizoxin);
- (t) Vitamin A and/or retinoic acids (*all-trans* retinoic acid and/or *13-cis* retinoic acid and/or *9-cis* retinoic acid) and/or one or more derivatives thereof (*all-trans* retinoic acid, *13-cis* retinoic acid, *all-trans* retinol, *9-cis* retinoic acid or 4-hydroxyphenylretinamide or retinyl esters such as *all-trans* retinyl acetate);
- (u) Vitamin D2 or vitamin D3 or 1α , 25-dihydroxyvitamin D3 or 25-hydroxyvitamin D3 or 1α , 24R, 25-trihydroxyvitamin D3; or 24, 25-dihydroxyvitamin D3
- (v) Zeaxanthin ((3R, 3'R)- β , β -carotene-3, 3'-diol) and/or one or more isomers and stereo-isomers (preferably mesozeaxanthin, 3R,3'S-zeaxanthin) and/or monoesters and/or diesters, preferably esters of saturated alkanoic acids, such as acetic, propionic, palmitic, stearic, and succinic acid, mono-unsaturated fatty acids, such as oleic acid, and poly-unsaturated fatty acids, such as linolic, linoleic, docosahexaenoic, and arachidonic acid, thereof;
- (w) Carnosic acid and/or one or more derivatives thereof;
- (x) Carnosol and/or one or more derivatives thereof;
- (y) Depudecin and/or one or more derivatives thereof;

- (z) Eponemycin and/or one or more derivatives thereof;
- (aa) Dihydroeponemycin and/or one or more derivatives thereof;
- (bb) Epoxomicin and/or one or more derivatives thereof;
- (cc) Ergosterol and/or one or more derivatives thereof;
- 5 (dd) Fisetin and/or one or more derivatives thereof;
- (ee) Fumagillin and/or one or more derivatives thereof;
- (ff) Lactacystin and/or one or more derivatives thereof;
- (gg) Luteolin and/or one or more derivatives thereof;
- (hh) Motuporamine C and/or one or more derivatives thereof;
- 10 (ii) Ovalicin and/or one or more derivatives thereof;
- (jj) Radicicol and/or one or more derivatives thereof;
- (kk) Squalamine and/or one or more derivatives thereof;
- (ll) Isoliquiritin, isoliquiritigenin, liquiritigenin and/or one or more derivatives thereof;
- 15 (mm) Very-long-chain omega-3 fatty acids (eicosapentaenoic acid [C20: 5, omega-3], decosahexaenoic acid [C22: 6, omega-3], polyunsaturated ω -3 fatty acids);
- (nn) Shark cartilage extract.
- (oo) Glucosinolate derivatives (Methylsulfinylalkyl glucosinolates, e.g. [1-methylsulfinylmethyl glucosinolate, 2-methylsulfinylethyl glucosinolate, 3-methylsulfinylpropyl glucosinolate (glucoiberin), 4-methylsulfinylbutyl glucosinolate (glucoraphanin), 5-methylsulfinylpentyl glucosinolate (glucoalysin), 6-methylsulfinylhexyl glucosinolate, 7-methylsulfinylheptyl glucosinolate, 8-methylsulfinyloctyl glucosinolate, 9-methylsulfinylnonyl glucosinolate, 10-methylsulfinyldodecyl glucosinolate] or allyl glucosinolate (sinigrin) or phenylethyl glucosinolate (gluconasturtiin) or 3-butenyl glucosinolate (gluconapin) or indol-3-ylmethyl glucosinolate (glucobrassicin) or derivatives thereof [N-methoxyindol-3-
- 20
- 25

ylmethyl glucosinolate (neoglucobrassicin), 4-hydroxyindol-3-ylmethyl glucosinolate (4-OH glucobrassicin), 4-methoxyindol-3-ylmethyl glucosinolate (4-CH₃O glucobrassicin)]).

- (pp) Isothiocyanate derivatives (Methylsulfinylalkyl isothiocyanate [1-methylsulfinylmethyl isothiocyanate, 2-methylsulfinylethyl isothiocyanate, 3-methylsulfinylpropyl isothiocyanate, 4-methylsulfinylbutyl isothiocyanate (sulforaphane), 5-methylsulfinylpentyl isothiocyanate, 6-methylsulfinylhexyl isothiocyanate (6-HITC), 7-methylsulfinylheptyl isothiocyanate, 8-methylsulfinyloctyl isothiocyanate, 9-methylsulfinylnonyl isothiocyanate, 10-methylsulfinyldodecyl isothiocyanate] or allyl isothiocyanate or phenylethyl isothiocyanate (PEITC) or 3-butenyl isothiocyanate or indole-3-ylmethylisothiocyanate) or derivatives thereof (N-methoxy indole-3-ylmethylisothiocyanate, 4-hydroxy indole-3-ylmethylisothiocyanate, 4-methoxy indole-3-ylmethylisothiocyanate) or 3-Indolemethanol (Indole-3-carbinol (I3C)).
- 15 Examples of non-cancerous symptoms and pathologies, which are associated with or favored by or caused by androgen signalling, or which incidence risks are associated with androgen signalling, or symptoms and pathologies which are sensitive to a reduction of androgen signalling comprise polycystic ovary syndrome, hyperandrogenic chronic anovulation, female infertility, ovarian hyperstimulation syndrome, cystic mastitis,
- 20 amenorrhea, oligomenorrhea, accumulation of abdominal fat, insulin resistance, hyperinsulinemia, type 2 diabetes mellitus, hypertension, hirsutism, feminine acne, alopecia, menstrual disorder, hyperandrogenism, SAHA syndrome (stands for seborrhea, acne, hirsutism on face, trunk and extremities and androgenetic alopecia of the scalp), congenital adrenal hyperplasia (CAH), stress induced disorders of androgen signalings
- 25 and benign prostatic hyperplasia (BPH).

Of primary interest for treatment in accordance with the present invention are polycystic ovary syndrome, insulin resistance, hyperinsulinemia, type 2 diabetes mellitus, hypertension, hirsutism, feminine acne, menstrual disorder hyperandrogenism and benign prostatic hyperplasia.

- 30 For the primary and secondary prevention and coadjuvant treatment of non-cancerous symptoms and/or pathologies sensitive to/associated with androgen signalling in accordance with the present invention, lycopene is administered to the subject or a mammal in need of such treatment, i.e. humans, pets or farm animals including birds and

fish, in an amount which leads to a reduction of androgen signalling. Such amount is preferably one that results in a plasma concentration of 0.01 to 6 μ M (micromolar) and may be within the range of from about 0.0005 mg/kg body weight to about 5 mg/kg body weight per day.

- 5 Optionally, lycopene is administered in combination with about 0.2 mg/kg body weight to about 30 mg/kg body weight of vitamin C per day and /or about 0.01 mg/kg body weight to about 15 mg/kg body weight of vitamin E per day.

In accordance with the present invention, lycopene or the combination of lycopene with vitamin C and/or vitamin E may, furthermore, be co-administered together with one or
 10 more of following ingredients within dosage ranges set forth below in "mg/kg" or " μ g/kg" or "ng/kg" meaning "mg/kg body weight" or " μ g/kg body weight" or "ng/kg body weight":

Silymarin	0.01mg/kg	to	100mg/kg
Silybin or equimolar amounts of derivatives	0.01mg/kg	to	100mg/kg
Isosilybin or equimolar amounts of derivatives	0.01mg/kg	to	100mg/kg
Silydianin or equimolar amounts of derivatives	0.01mg/kg	to	100mg/kg
Silychristin or equimolar amounts of derivatives	0.01mg/kg	to	100mg/kg
Extract of Saw Palmetto (lipophilic (liposterolic) berry extract containing 80 to 90 percent fatty acids) or equimolar amounts of its components mentioned above	0.01mg/kg	to	100mg/kg
Genistein aglycone	0.015mg/kg	to	6mg/kg
Apigenin	0.01mg/kg	to	500mg/kg
Quercetin	0.001mg/kg	to	300mg/kg
Myricetin	0.001mg/kg	to	300mg/kg
Kampferol	0.001mg/kg	to	300mg/kg

- 9 -

Resveratrol or equimolar amounts of derivatives	0.01mg/kg	to	1.5mg/kg
Curcumin or equimolar amounts of components or derivatives mentioned above	0.01mg/kg	to	200mg/kg
Flufenamic acid	0.01mg/kg	to	200mg/kg
Geldanamycin	0.01mg/kg	to	200mg/kg
Extract of <i>Stephania hernandifolia</i> , or equimolar amounts of its components mentioned above	0.001mg/kg	to	300mg/kg
Extract of <i>Myrica rubra</i> , or equimolar amounts of its components mentioned above	0.001mg/kg	to	300mg/kg
Astaxanthin	0.001mg/kg	to	5mg/kg
β -Carotene	0.001mg/kg	to	5mg/kg
β -Cryptoxanthin	0.001mg/kg	to	5mg/kg
(-)-epigallocatechin gallate (EGCG) or (-)-epicatechin gallate (ECG)	0.5mg/kg	to	15mg/kg
or equimolar amounts of derivatives mentioned above			
Lutein	0.001mg/kg	to	5mg/kg
Rhizoxin	0.001mg/kg	to	20mg/kg
Palmitoyl Rhizoxin	0.001mg/kg	to	20mg/kg
Retinoic acid or equimolar amounts of derivatives mentioned above	0.001mg/kg	to	5mg/kg
All- <i>trans</i> Retinol	3 μ g/kg	to	100 μ g/kg
All- <i>trans</i> Retinyl acetate	3.5 μ g/kg	to	115 μ g/kg
All- <i>trans</i> Retinol palmitate	5.5 μ g/kg	to	180 μ g/kg
Vitamin D2 (Ergocalciferol)	0.1ng/kg	to	10 μ g/kg
Vitamin D3 (Cholecalciferol)	0.1ng/kg	to	10 μ g/kg

- 10 -

1 α , 25-Dihydroxyvitamin D3	0.1ng/kg	to	0.5 μ g/kg
25-Hydroxyvitamin D3	0.1ng/kg	to	10 μ g/kg
1 α , 24R, 25-Trihydroxyvitamin D3	0.1ng/kg	to	0.5 μ g/kg
24, 25-Dihydroxyvitamin D3	0.1ng/kg	to	10 μ g/kg
Zeaxanthin	0.001mg/kg	to	5mg/kg
Carnosic acid	0.001mg/kg	to	250mg/kg
Carnosol	0.001mg/kg	to	250mg/kg
Depudecin	0.01mg/kg	to	500mg/kg
Eponemycin	0.01mg/kg	to	500mg/kg
Dihydroeponemycin	0.01mg/kg	to	500mg/kg
Epoxomicin	0.01mg/kg	to	500mg/kg
Ergosterol	0.1mg/kg	to	2000mg/kg
Fisetin	0.01mg/kg	to	500mg/kg
Fumagillin	0.1mg/kg	to	300mg/kg
Lactacystin	0.01mg/kg	to	250mg/kg
Luteolin	0.01mg/kg	to	100mg/kg
Motuporamine C	0.1mg/kg	to	500mg/kg
Ovalicin	0.1mg/kg	to	250mg/kg
Radicicol	0.1mg/kg	to	1000mg/kg
Squalamine	0.001	to	200mg/kg
Isoliquiritin	1ng/kg	to	1mg/kg
Isoliquiritigenin	1ng/kg	to	1mg/kg
Very-long-chain omega-3 fatty acids, e.g. eicosapentaenoic acid [C20: 5, omega-3] or equimolar amounts of very-long-chain omega-3 fatty acids mentioned above	0.001g/kg	to	0.05g/kg
Shark cartilage extract	0.001g/kg	to	0.1g/kg

Glucosinolate derivatives 0.01mg/kg to 200mg/kg

e.g. 4-methylsulfinylbutyl glucosinolate
(glucoraphanin) or equimolar amounts of
glucosinolate derivatives mentioned above

Isothiocyanate derivatives or I3C 0.001mg/kg to 200mg/kg

e.g. 4-methylsulfinylbutyl isothiocyanate
(sulforaphane) or equimolar amounts of
isothiocyanate derivatives mentioned above

Lycopene or a combination of lycopene, vitamin C and/or vitamin E, optionally together
with compounds (a) to (pp) can find use in accordance with the present invention for the
5 completion of human nutrition, nutrition of pets and farm animals, or medical treatment
of subjects, especially mammals.

Said compounds may be provided as the active ingredient in compositions, preferably for
enteral application, which may be solid or liquid galenical formulations, dietary
compositions or animal feed compositions. Examples of solid galenical formulations are
10 tablets, capsules (e.g. hard or soft shell gelatin capsules), pills, sachets, powders, granules
and the like which contain the active ingredient together with conventional galenical
carriers. Any conventional carrier material can be utilized. The carrier material can be
organic or inorganic inert carrier material suitable for oral administration. Suitable
carriers include water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc,
15 vegetable oils, and the like. Additionally, additives such as flavouring agents, preservatives,
stabilizers, emulsifying agents, buffers and the like may be added in accordance with
accepted practices of pharmaceutical compounding. They may also be used in dietary
compositions which may be a food, a food premix or a fortified food or a beverage. While
the individual active ingredients are suitably administered in a single composition they
20 may also be administered in individual dosage units.

Preferably lycopene is used in accordance with the present invention together with vitamin
E, or with vitamin C or with vitamin C and vitamin E. Preferred additional components
are as additional active ingredients compound (a), (b), (c), (e), (f), (h), (i), (l), (m), (n),
(o), (p), (q), (r), (t), (u), (v), (w), (x), (mm), (oo), (pp), more preferably the active
25 ingredients are (a), (b), (c), (e), (f) (h), (i), (o), (q), (r), (v), (mm) and (pp).

Particularly preferred is the administration of the following active ingredients:

Lycopene, in a concentration so that the daily consumption by a human adult is in the range of from 0.25mg/day to 50mg/day, preferably from 0.2mg/day to 30mg/day; optionally in combination with

- 5 Vitamin C or its derivative, in a concentration so that the daily consumption by a human adult is in the range of from 50mg/day to 1000mg/day; and/or

Vitamin E or its derivative, in a concentration so that the daily consumption by a human adult is in the range of from 15mg/day to 600mg/day; and/or

- 10 Silymarin (extract from *Silybum marianum*) and/or its four main components (silybin and/or isosilybin and/or silydianin and/or silychristin), in a concentration so that the daily consumption by a human adult of Silymarin or its four main components (silybin, isosilybin, silydianin, silychristin), respectively, is in the range of from 1mg/day to 1000mg/day, preferably from 50mg/day to 800mg/day; and/or

- 15 Saw palmetto (lipophilic extract of *Sabal serrulata*, syn. *Serenoa repens*, containing phytosterols and 80 to 90 percent fatty acids) and/or its main components (lauric acid, oleic acid, myristic acid, palmitic acid, sitosterol, campesterol, stigmasterol, cycloartenol, sitostanol, campestanol) and/or derivatives thereof (long-chain fatty acyl ester, ferrulate ester, glycosides)) in a concentration so that the daily consumption by a human adult of saw palmetto or equimolar amounts of its main components is in the range of from
20 1mg/day to 1000mg/day, preferably from 50mg/day to 250mg/day; and/or

Genistein, in a concentration so that the daily consumption by a human adult is in the range of from 20mg/day to 200mg/day; and/or

Quercetin, in a concentration so that the daily consumption by a human adult is in the range of from 1mg/day to 500mg/day; and/or

- 25 Myricetin, in a concentration so that the daily consumption by a human adult is in the range of from 1mg/day to 500mg/day; and/or

Resveratrol, in a concentration so that the daily consumption by a human adult is in the range of from 5 mg/day to 50 mg/day; and/or

- Curcumin (effects of *Curcuma Longa*) or equimolar amount of derivatives thereof (demethoxy-curcumin, bis-demethoxycurcumin, sodium curcumin, bis-demethylcurcumin, tetrahydrocurcumin, hexahydrocurcumin, diacetylcurcumin, triethylcurcumin) and/or equimolar amount of its main components (curcumin (diferuloylmethane), demethoxycurcumin, bisdemethoxycurcumin) and/or derivatives thereof (glucuronides, sulfates), in a concentration so that the daily consumption by a human adult is in the range of from 10mg/day to 1000mg/day, preferably from 50mg/day to 800mg/day; and/or
- 10 β -Carotene, in a concentration so that the daily consumption by a human adult is in the range of from 0.1 mg/day to 20mg/day, preferably from 2mg/day to 10 mg/day; and/or
- (-)-Epigallocatechin gallate (EGCG), in a concentration so that the daily consumption by a human adult is in the range of from 50mg/day to 500mg/day; and/or
- Lutein, in a concentration so that the daily consumption by a human adult is in the range of from 0.1mg/day to 50mg/day, preferably from 0.25mg/day to 30mg/day; and/or
- 15 Zeaxanthin, in a concentration so that the daily consumption by a human adult is in the range of from 0.1mg/day to 50mg/day, preferably from 0.25mg/day to 30mg/day, and/or
- of very-long-chain omega-3 fatty acids, e.g. eicosapentaenoic acid [C20: 5, omega-3] or equimolar amounts of very-long-chain omega-3 fatty acids, in a concentration so that the daily consumption by a human adult is in the range of from 1mg/day to 500mg/day,
- 20 and/or
- Isothiocyanate derivatives or I3C, e.g. 4-methylsulfinylbutyl isothiocyanate (sulforaphane) or equimolar amounts of isothiocyanate derivatives mentioned above, in a concentration so that the daily consumption by a human adult is in the range of from 0.1mg/day to 50mg/day, preferably from 0.25mg/day to 30mg/day.
- 25 Typical examples of galenic formulations for use in accordance with the present invention are given below. The Examples are for the purpose of illustrating the invention and are not intended to limit the scope of the invention in any way.

The following Examples illustrate the invention further.

Example 1

A tablet for the coadjuvant treatment of feminine acne is formulated to contain 5 mg of lycopene, 200 mg of vitamin E, 250 mg of vitamin C, 37.5 mg of resveratrol. The daily dose corresponds to said amounts in form of two tablets with half of said amounts each.

Example 2

- 5 A tablet for the prevention of polycystic ovary syndrome is formulated to contain 2.5 mg of lycopene, 250 mg of vitamin E, 100 mg of vitamin C, 100mg silymarin.